Search Results

You are looking at 61 - 70 of 549 items for :

  • neuroendocrine cancer x
  • All content x
Clear All
Free access

Y Capodanno, F O Buishand, L Y Pang, J Kirpensteijn, J A Mol, and D J Argyle

Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors . Gastroenterology 141 1728 – 1737 . ( ) 21806944 10.1053/j.gastro.2011.07.037 Gordon I Paoloni M Mazcko

Free access

Sara Molatore, Andrea Kügler, Martin Irmler, Tobias Wiedemann, Frauke Neff, Annette Feuchtinger, Johannes Beckers, Mercedes Robledo, Federico Roncaroli, and Natalia S Pellegata

B are associated with small bowel neuroendocrine tumors . Cancer Genetics 28 564 – 570 . ( ) McComb DJ Kovacs K Beri J Zak F 1984 Pituitary adenomas in old Sprague-Dawley rats

Restricted access

Satya Das, Liping Du, Aimee Schad, Shikha Jain, Aaron Jessop, Chirayu Shah, David Eisner, Dana Cardin, Kristen Ciombor, Laura Goff, Marques Bradshaw, Dominique Delbeke, Martin Sandler, and Jordan Berlin

Akirov A Larouche V Alshehri S Asa SL Ezzat S 2019 Treatment options for pancreatic neuroendocrine tumors . Cancers 11 E828. ( ) Ballal S Yadav M Bal C Sahoo R Tripathi M 2019

Free access

Joanna Grey and Kym Winter

-0054 ) 10.1530/EC-16-0054) Barakat MT Meeran K Bloom SR 2004 Neuroendocrine tumours . Endocrine-Related Cancer 11 1 – 18 . ( ) 15027882 10.1677/erc.0.0110001 Brandi ML Gagel RF Angeli A Bilezikian JP

Free access

Daniela Molè, Teresa Gagliano, Erica Gentilin, Federico Tagliati, Claudio Pasquali, Maria Rosaria Ambrosio, Giancarlo Pansini, Ettore C degli Uberti, and Maria Chiara Zatelli

secretion and growth in human neuroendocrine tumor cells . Cancer Research 60 4573 – 4581 . Wiegand C Hipler U 2008 Methods for the measurement of cell and tissue compatibility including tissue regeneration processes . GMS Krankenhaushygiene

Open access

Jan P Dumanski, Chiara Rasi, Peyman Björklund, Hanna Davies, Abir S Ali, Malin Grönberg, Staffan Welin, Halfdan Sorbye, Henning Grønbæk, Janet L Cunningham, Lars A Forsberg, Lars Lind, Erik Ingelsson, Peter Stålberg, Per Hellman, and Eva Tiensuu Janson

for the offspring of parents having any cancer or specifically a neuroendocrine tumor is about 4.5–6.5 times higher than that in the rest of the population ( Hemminki & Li 2001 , Hiripi et al . 2009 , Neklason et al . 2016 ). The relative risk of

Free access

Saila Kauhanen, Marko Seppänen, Jari Ovaska, Heikki Minn, Jörgen Bergman, Pirkko Korsoff, Pasi Salmela, Juha Saltevo, Timo Sane, Matti Välimäki, and Pirjo Nuutila

neuroendocrine cancer . Surgical Oncology Clinics of North America 16 627 – 637 .

Free access

Pauline Croisé, Sébastien Houy, Mathieu Gand, Joël Lanoix, Valérie Calco, Petra Tóth, Laurent Brunaud, Sandra Lomazzi, Eustache Paramithiotis, Daniel Chelsky, Stéphane Ory, and Stéphane Gasman

for GTP, and their inactivation requires GTPase-activating proteins (GAPs) that catalyze GTP hydrolysis by the Rho GTPases ( Cherfils & Zeghouf 2013 ). Rho GTPases regulate many cellular processes related to cancer biology, including cell cycle

Free access

P A Abrahamsson

The prognostic significance of neuroendocrine differentiation in prostatic malignancy is controversial, but the results of recent studies with markers such as chromogranin A and neurone-specific enolase suggest that neuroendocrine differentiation, as reflected by increased tissue expression or blood concentrations of these neuroendocrine secretory products, is associated with a poor prognosis, tumour progression, and androgen independence. As all malignant neuroendocrine cells are devoid of androgen receptors and the expression of neuroendocrine cells is not suppressed by androgen ablation, clonal propagation of androgen receptor-negative neuroendocrine cells may have an important role in the development of androgen-independent prostatic carcinoma. This has significant implications for the treatment of prostate cancer, because several of the hormones that are secreted by neuroendocrine differentiated, malignant prostatic cells are potential candidates for use in drug treatment. A limited number of hormones have been tested in this context, in particular somatostatin, bombesin, and serotonin. As there is currently no successful treatment for differentiated prostate cancer, new therapeutic procedures and trials need to be developed to test drugs based on neuroendocrine hormones or their antagonists.

Restricted access

A H Bootsma, C H J van Eijck, L J Hofland, and S W J Lamberts